After finishing at $0.75 in the prior trading day, VolitionRX Ltd (AMEX: VNRX) closed at $0.74, down -0.91%. In other words, the price has decreased by -$0.0068 from its previous closing price. On the day, 574128 shares were traded. VNRX stock price reached its highest trading level at $0.7700 during the session, while it also had its lowest trading level at $0.7000.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
Our goal is to gain a better understanding of VNRX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.69 and its Current Ratio is at 0.69.
On March 10, 2021, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $8.Cantor Fitzgerald initiated its Overweight rating on March 10, 2021, with a $8 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 02 ’24 when Eight Corp Ltd sold 20,000 shares for $0.90 per share. The transaction valued at 18,000 led to the insider holds 298,419 shares of the business.
Butera Salvatore Thomas bought 10,000 shares of VNRX for $8,300 on Dec 18 ’23. The CEO – Volition Veterinary now owns 99,350 shares after completing the transaction at $0.83 per share. On Dec 15 ’23, another insider, Butera Salvatore Thomas, who serves as the CEO – Volition Veterinary of the company, bought 10,000 shares for $0.77 each. As a result, the insider paid 7,700 and bolstered with 89,350 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VNRX now has a Market Capitalization of 58.46M and an Enterprise Value of 43.59M. For the stock, the TTM Price-to-Sale (P/S) ratio is 74.96. Its current Enterprise Value per Revenue stands at 66.96 whereas that against EBITDA is -1.34.
Stock Price History:
Over the past 52 weeks, VNRX has reached a high of $2.10, while it has fallen to a 52-week low of $0.55. The 50-Day Moving Average of the stock is 0.9892, while the 200-Day Moving Average is calculated to be 1.0229.
Shares Statistics:
The stock has traded on average 187.11K shares per day over the past 3-months and 210.96k shares per day over the last 10 days, according to various share statistics. A total of 81.90M shares are outstanding, with a floating share count of 57.18M. Insiders hold about 27.33% of the company’s shares, while institutions hold 8.09% stake in the company. Shares short for VNRX as of Feb 29, 2024 were 501.69k with a Short Ratio of 2.58, compared to 598.54k on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 0.64% and a Short% of Float of 0.84%.
Earnings Estimates
Its stock is currently analyzed by 3 different market analysts. On average, analysts expect EPS of -$0.11 for the current quarter, with a high estimate of -$0.11 and a low estimate of -$0.11, while EPS last year was -$0.15. The consensus estimate for the next quarter is -$0.11, with high estimates of -$0.11 and low estimates of -$0.11.
Analysts are recommending an EPS of between -$0.36 and -$0.44 for the fiscal current year, implying an average EPS of -$0.41. EPS for the following year is -$0.33, with 2 analysts recommending between -$0.31 and -$0.36.
Revenue Estimates
3 analysts predict $610k in revenue for the current quarter. It ranges from a high estimate of $840k to a low estimate of $500k. As of the current estimate, VolitionRX Ltd’s year-ago sales were $420k, an estimated increase of 45.20% from the year-ago figure. For the next quarter, 3 analysts are estimating revenue of $910k, an increase of 321.30% over than the figure of $45.20% in the same quarter last year. There is a high estimate of $1.12M for the next quarter, whereas the lowest estimate is $700k.
A total of 3 analysts have provided revenue estimates for VNRX’s current fiscal year. The highest revenue estimate was $5.47M, while the lowest revenue estimate was $3.3M, resulting in an average revenue estimate of $4.49M. In the same quarter a year ago, actual revenue was $775k, up 479.40% from the average estimate. Based on 2 analysts’ estimates, the company’s revenue will be $19.98M in the next fiscal year. The high estimate is $21.8M and the low estimate is $18.17M. The average revenue growth estimate for next year is up 345.00% from the average revenue estimate for this year.
